FluidDA is the leading company in the research and development of imaging biomarkers to enhance drug development and patient care. Collaboration with universities and medical research centers resulted in clinical trials including a total of 750 patients. These trials proved the higher sensitivity of this novel approach over existing standard outcome parameters such as spirometry in the respiratory field. FluidDA is currently active as a CRO and research company in:
- Pulmonology and respiratory drug delivery
- Sleep medicine
- Maxillofacial surgery
- Cardiovascular
